OMDA Omada Health, Inc.
Services-Health Services · Nasdaq · SEC CIK 1611115 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY43.3%
TTM net income YoY153.6%
TTM EPS YoY124.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin70.7%
Operating margin2.1%
Net margin4.2%
FCF margin8.5%
EBITDA margin3.9%
Returns
ROE5.7%
ROA4.4%
ROIC (approx.)28.2%
Asset turnover1.05x
Leverage & solvency
Liabilities / assets21.6%
Debt / equity0.00x
Current ratio4.18x
Interest coverage22.37x
Cash quality & payout
Operating cash flow / net income2.04x
Accruals ratio-4.6%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $91.31M | $87.83M | $78.05M | $75.85M | $68.03M | $61.37M | $54.96M | $47.98M |
| Cost of revenue | $22.02M | $24.05M | $29.36M | $22.18M | $22.96M | $21.07M | $23.06M | $15.85M |
| Gross profit | $69.28M | $63.79M | $48.69M | $53.66M | $45.07M | $40.31M | $31.90M | $32.13M |
| R&D expense | $15.27M | $14.62M | $12.70M | $11.55M | $10.30M | $10.02M | $8.81M | $9.19M |
| SG&A expense | $20.08M | $15.72M | $13.99M | $14.22M | $14.34M | $12.31M | $11.32M | $11.95M |
| Operating income | $4.82M | $3.55M | -$4.78M | $3.28M | -$2.51M | -$4.34M | -$8.40M | -$7.10M |
| Interest expense | $262,000 | $14,000 | $18,000 | $13,000 | $353,000 | $1.09M | $1.07M | $1.10M |
| Pretax income | $6.55M | $5.29M | -$2.97M | $5.16M | -$3.18M | -$5.31M | -$9.45M | -$8.25M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | $6.55M | $5.29M | -$2.97M | $5.16M | -$3.18M | -$5.31M | -$9.45M | -$8.25M |
| EBITDA | $6.50M | $5.13M | -$3.27M | $4.73M | -$1.15M | -$2.99M | -$7.06M | -$5.82M |
| EPS (basic) | 0.11 | 0.09 | -0.05 | — | -0.06 | -0.24 | -1.15 | — |
| EPS (diluted) | 0.10 | 0.08 | -0.05 | — | -0.06 | -0.24 | -1.15 | — |
| Weighted avg. shares (diluted) | 67.12M | 63.95M | 58.92M | — | 57.66M | 21.97M | 8.24M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $243.15M | $221.71M | $211.76M | $222.04M | $198.63M | $223.15M | $59.40M | $76.39M |
| Receivables | $48.19M | $56.57M | $39.98M | $34.59M | $41.45M | $33.29M | — | $23.42M |
| Inventory | $4.88M | $4.12M | $3.83M | $4.49M | $3.15M | $3.47M | — | $3.30M |
| Current assets | $315.06M | $294.91M | $269.43M | $272.93M | $254.90M | $271.11M | — | $113.06M |
| PP&E, net | $9.74M | $9.10M | $8.46M | $7.94M | $7.54M | $6.48M | — | $5.62M |
| Goodwill | $13.24M | $13.24M | $13.24M | $13.24M | $13.24M | $13.24M | — | $13.24M |
| Intangibles | $1.10M | $1.54M | $1.98M | $2.41M | $2.85M | $3.29M | — | $4.26M |
| Total assets | $348.54M | $328.22M | $302.80M | $305.41M | $287.47M | $302.97M | — | $150.89M |
| Current liabilities | $75.38M | $75.48M | $68.68M | $75.73M | $70.12M | $57.99M | — | $53.95M |
| Long-term debt | — | — | — | $0 | $0 | $29.97M | — | $29.77M |
| Total debt | — | — | — | $0 | $0 | $29.97M | — | $29.77M |
| Total liabilities | $75.38M | $75.48M | $68.68M | $75.73M | $70.12M | $88.76M | — | $86.26M |
| Shareholders' equity | $273.16M | $252.74M | $234.12M | $229.68M | $217.35M | $214.21M | -$390.05M | -$384.40M |
| Net debt | — | — | — | -$222.04M | -$198.63M | -$193.18M | — | -$46.62M |
| Shares outstanding | 62.00M | 60.61M | 59.24M | 58.43M | 57.89M | 57.32M | — | 8.16M |
| Cash flow statement | ||||||||
| Operating cash flow | $15.14M | $4.01M | -$11.83M | $21.38M | $10.13M | $2.86M | -$16.12M | -$6.49M |
| Capital expenditure | $118,000 | $146,000 | $78,000 | $199,000 | $537,000 | $271,000 | $315,000 | $184,000 |
| Free cash flow | $15.02M | $3.86M | -$11.91M | $21.18M | $9.60M | $2.59M | -$16.43M | -$6.67M |
| Investing cash flow | -$1.63M | -$1.66M | -$1.56M | -$1.35M | -$1.99M | -$1.25M | -$1.25M | -$969,000 |
| Financing cash flow | $7.93M | $7.60M | $3.12M | $3.38M | -$32.66M | $162.14M | $372,000 | $113,000 |
| Depreciation & amortization | $1.68M | $1.58M | $1.51M | $1.45M | $1.36M | $1.35M | $1.33M | $1.28M |
| Stock-based compensation | $5.85M | $5.63M | $4.21M | $3.75M | $3.54M | $2.83M | $2.84M | $2.31M |
Free plan shows the latest 8 periods; Pro shows all 11 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.